# Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

> **NCT03806790** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 182 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 90100 foam
- **DRUG:** Dovobet® ointment

## Key facts

- **NCT ID:** NCT03806790
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-24
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-06-10
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806790, "Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03806790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*